Naveris, a Natick, MA-based commercial-stage life sciences company, raised $33.4M in expansion of Series A funding.
The round, which brought total funding to $51m, was led by Gurnet Point Capital, with participation from TechU Ventures and BrightEdge.
The company intends to use the funds to advance commercialization of NavDx, its flagship blood test for the early detection of cancers caused by the human papillomavirus (HPV), and to generate the clinical data needed to expand into other cancer types and indications.
Led by CEO Piyush B. Gupta, Naveris is a biotechnology company whose mission is to improve outcomes for people at risk of developing viral cancers through novel molecular diagnostics that enable earlier disease detection. The company’s blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.
Along with Naveris’ commercial activities, more than 25 medical institutions have partnered with the company to conduct clinical studies and trials utilizing its technology. Naveris has also partnered with biotechnology companies developing immunotherapies for HPV-related cancers.
FinSMEs
27/09/2022